DNTH vs LIN · rev $6.2M vs P/E 34, rev $33.99B
Dianthus Therapeutics Inc. (DNTH) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
Dianthus Therapeutics Inc. (DNTH) is a biotechnology company listed on US.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported DNTH revenue for 2024-12-31 was $6.2M. Net income was -$85.0M. Revenue was up 120.6% from 2023-12-31 to 2024-12-31. DNTH currently screens at market cap $4.40B.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
DNTH currently screens at market cap $4.40B. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the DNTH and LIN stock pages for the full models.
Not investment advice.